Mitigation of chronic glucotoxicity-mediated skeletal muscle atrophy by arachidonic acid

Life Sci. 2023 Nov 15:333:122141. doi: 10.1016/j.lfs.2023.122141. Epub 2023 Oct 3.

Abstract

Toxicity caused by chronic hyperglycemia is a significant factor affecting skeletal muscle myogenesis, resulting in diabetic myopathy. Chronic and persistent hyperglycemia causes activation of the atrophy-related pathways in the skeletal muscles, which eventually results in inflammation and muscle degeneration. To counteract this process, various bioactive compound has been studied for their reversal or hypertrophic effect. In this study, we explored the molecular mechanisms associated with reversing glucotoxicity's effect in C2C12 cells by arachidonic acid (AA). We found a substantial increase in the pro-inflammatory cytokines and ROS production in hyperglycemic conditions, mitigated by AA supplementation. We found that AA supplementation restored protein synthesis that was downregulated under glucotoxicity conditions. AA enhanced myogenesis by suppressing high glucose induced inflammation and ROS production and enhancing protein synthesis. These results imply that AA has cytoprotective actions against hyperglycemia-induced cytotoxicity.

Keywords: Arachidonic acid; Bioactive lipid; Glucotoxicity; Muscle atrophy; Muscle degeneration.

MeSH terms

  • Arachidonic Acid / metabolism
  • Humans
  • Hyperglycemia* / metabolism
  • Inflammation / pathology
  • Muscle, Skeletal / metabolism
  • Muscular Atrophy* / metabolism
  • Reactive Oxygen Species / metabolism

Substances

  • Arachidonic Acid
  • Reactive Oxygen Species